Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,602.659 |
Reported balance
After 2026-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-14 · Exercise / conversion · Acquired 148 · Balance 1,602.659 F1: Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025 and December 31, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 1,790.659 |
Reported balance
After 2026-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 188 · Balance 1,790.659 |
| Common StockSEC Table I · non-derivative | Direct | 2,091.659 |
Reported balance
After 2026-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-14 · Exercise / conversion · Acquired 301 · Balance 2,091.659 |
| Common StockSEC Table I · non-derivative | Direct | 2,458.659 |
Reported balance
After 2026-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-02-14 · Exercise / conversion · Acquired 367 · Balance 2,458.659 |
| Common StockSEC Table I · non-derivative | Direct | 2,156.659 |
Reported balance
After 2026-02-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-02-14 · Tax withholding · Disposed 302 · Balance 2,156.659 F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 5,361 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Grant · Acquired 5,361 · Balance 5,361 F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,262 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Grant · Acquired 1,262 · Balance 1,262 F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,620 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Grant · Acquired 1,620 · Balance 1,620 F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-14 · Exercise / conversion · Disposed 148 · Balance 0 F7: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 188 |
Reported balance
After 2026-02-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-14 · Exercise / conversion · Disposed 188 · Balance 188 F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 602 |
Reported balance
After 2026-02-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-14 · Exercise / conversion · Disposed 301 · Balance 602 F9: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,101 |
Reported balance
After 2026-02-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-02-14 · Exercise / conversion · Disposed 367 · Balance 1,101 F10: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025 and December 31, 2025.
F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027.
F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027.
F7: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
F9: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
F10: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2022 Filed Sep 6, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 19 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017058 · doc1.xml · nonDerivative · entry 1 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 20 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022 and June 30, 2022. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004786 · doc1.xml · derivative · entry 5 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Underlying: Common Stock · 593 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2025. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2025. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2025. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004786 · doc1.xml · derivative · entry 4 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 593 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004786 · doc1.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,043 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004786 · doc1.xml · derivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,043 Underlying: Common Stock · 5,043 shares Expires 2032-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 74 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74 Underlying: Common Stock · 74 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 588 | Not disclosed Strike: $690.70 | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2031-08-31 F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning September 1, 2022. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 124 | Not disclosed Strike: $690.70 | Not disclosed |
DisclosureSEC source: 0001567619-21-016750 · doc1.xml · derivative · entry 1 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124 Underlying: Common Stock · 124 shares Expires 2031-08-31 F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning September 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.